Editorial: Antimicrobial Peptides: Molecular Design, Structure-Function Relationship, and Biosynthesis Optimization

Hao, Ya; Wang, Jianhua; Fuente-Núñez, César de la; Franco, Octávio Luiz

doi:10.3389/fmicb.2022.888540

Cited by 22 publications

(21 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…AMPs could cover the merits of antibiotics in disease treatment and vaccines in disease prevention, and avoid their shortcomings, such as high resistance and high variation in pathogens, and high residue in animals. AMPs, antibiotics, and vaccines could complement each other, and build an iron triangle of animal health care together to halt the development of drug resistance and reduce the residues in tissues ( Teng et al, 2014 ; Zhang et al, 2014 ; Hao et al, 2017 , 2022 ; Li Z. et al, 2017 ; Yang et al, 2017 , 2019 ; Wang et al, 2018 ; Liu et al, 2021 ; Zheng et al, 2021 ). Therefore, it has been highly expected that AMPs could exert a positive contribution to support green husbandry in terms of a new health concept One World and One Health.…”

Section: Introductionmentioning

confidence: 99%

Effect of NZ2114 against Streptococcus dysgalactiae biofilms and its application in murine mastitis model

Yang

Zhang²,

Mao³

et al. 2022

Front. Microbiol.

Self Cite

View full text Add to dashboard Cite

Bovine mastitis caused by Streptococcus dysgalactiae (S. dysgalactiae) is usually treated with antibiotics, which may potentially increase drug resistance as the abuse. NZ2114, a variant of fungal defensin plectasin, displayed a potent antibacterial activity against S. dysgalactiae. The inhibition/eradication effect of the antimicrobial peptide NZ2114 on the early/mature biofilm of S. dysgalactiae CVCC 3938 was evaluated, as well as the elimination of bacteria in mature biofilms. In this study, NZ2114 displayed potent antibacterial activity against S. dysgalactiae CVCC 3938 and three clinical isolated S. dysgalactiae strains (0.11-0.45 μM). The early biofilm inhibition of S. dysgalactiae CVCC 3938 was 55.5–85.9% after treatment with NZ2114 at concentrations of 1–16 × MIC, which was better than that of vancomycin at the same concentration. The mature biofilm eradication rate was up to 92.7–97.6% with the increasing concentration (2–16 × MIC) of NZ2114, and the eradication rate did not change significantly with further increase of NZ2114 concentration, while the biofilm eradication rate of vancomycin-treated group at the same concentration remained at 92.5%. NZ2114 reduced the number of persister bacteria in biofilm. Scanning electron microscopy (SEM) and confocal laser scanning microscopy (CLSM) further demonstrated that NZ2114 could effectively reduce the biofilm thickness and bacterial number of S. dysgalactiae CVCC 3938. In vivo therapeutic effect of NZ2114 on murine mastitis model showed that NZ2114 was better than vancomycin in alleviating mammary gland inflammation by regulating cytokines production, inhibiting bacterial proliferation, and reducing the number of mammary gland bacteria. These data suggested that NZ2114 is a potential peptide candidate for the treatment of mastitis.

show abstract

Section: Introductionmentioning

confidence: 99%

Effect of NZ2114 against Streptococcus dysgalactiae biofilms and its application in murine mastitis model

Yang

Zhang²,

Mao³

et al. 2022

Front. Microbiol.

Self Cite

View full text Add to dashboard Cite

show abstract

“…Additionally, AMPs proved to be potent in inhibiting or eradicating intracellular organisms (Brinch et al, 2009 ; Wang et al, 2018 , 2019 ; Li et al, 2020b , 2021 ). Also, the iron triangle theory on health protection from AMPs, antibiotics, and vaccines for maintaining a reasonable equilibrium among pathogens, antimicrobials, and drug resistances has been recently put forward (Zheng et al, 2021 ; Hao et al, 2022 ). Given those merits, AMPs have been considered as promising and new therapeutic anti-infection candidates, and should exert more roles in health practices of humans and animals.…”

Section: Introductionmentioning

confidence: 99%

Pharmacokinetics and Pharmacodynamics of Fungal Defensin NZX Against Staphylococcus aureus-Induced Mouse Peritonitis Model

et al. 2022

Self Cite

View full text Add to dashboard Cite

Staphylococcus aureus (S. aureus) is one of the most common pathogenic bacteria responsible for causing a life-threatening peritonitis disease. NZX, as a variant of fungal defensin plectasin, displayed potent antibacterial activity against S. aureus. In this study, the antibacterial and resistance characteristics, pharmacokinetics, and pharmacodynamics of NZX against the S. aureus E48 and S. aureus E48-induced mouse peritonitis model were studied, respectively. NZX exhibited a more rapid killing activity to S. aureus (minimal inhibitory concentration, 1 μg/ml) compared with linezolid, ampicillin and daptomycin, and serial passaging of S. aureus E48 for 30 days at 1/2 × MIC, NZX had a lower risk of resistance compared with ampicillin and daptomycin. Also, it displayed a high biocompatibility and tolerance to physiological salt, serum environment, and phagolysosome proteinase environment, except for acid environment in phagolysosome. The murine serum protein-binding rate of NZX was 89.25% measured by ultrafiltration method. Based on the free NZX concentration in serum after tail vein administration, the main pharmacokinetic parameters for T1/2, Cmax, Vd, MRT, and AUC ranged from 0.32 to 0.45 h, 2.85 to 20.55 μg/ml, 1469.10 to 2073.90 ml/kg, 0.32 to 0.56 h, and 1.11 to 8.89 μg.h/ml, respectively. Additionally, the in vivo pharmacodynamics against S. aureus demonstrated that NZX administrated two times by tail vein at 20 mg/kg could rescue all infected mice in the lethal mouse peritonitis model. And NZX treatment (20 mg/kg) significantly reduced CFU counts in the liver, lung, and spleen, especially for intracellular bacteria in the peritoneal fluid, which were similar or superior to those of daptomycin. In vivo efficacies of NZX against total bacteria and intracellular bacteria were significantly correlated with three PK/PD indices of ƒAUC/MIC, ƒCmax/MIC, and ƒT% > MIC analyzed by a sigmoid maximum-effect model. These results showed that NZX may be a potential candidate for treating peritonitis disease caused by intracellular S. aureus.

show abstract

“…In this context, AMP are promising molecules capable of mediating the signaling of toll-like receptors, which makes them a therapeutic opportunity for the previously mentioned diseases ( Cook et al, 2004 ; Anwar et al, 2019 ). AMPs are the organism’s initial line of defense against infections ( Hao et al, 2022 ). These molecules exert various biological functions within the immune response, including cells’ recruitment of monocytes, neutrophils, and immature dendritic cells, inhibition of pro-inflammatory responses, stimulation of cell proliferation, angiogenesis, and wound healing promotion ( da Silva and Machado, 2012 ; Hancock et al, 1995 ; Zhang et al, 2021 ).…”

Section: Introductionmentioning

confidence: 99%

“…Many AMPs have been discovered and isolated, and the vast majority have a positive net charge and helical structures ( Hao et al, 2022 ). The liquid cationic characteristic of AMPs attributes an electrostatic attraction to LPS present in the cell wall of Gram-negative bacteria ( Sun and Shang, 2015 ).…”

Section: Introductionmentioning

confidence: 99%

Antimicrobial peptides could antagonize uncontrolled inflammation via Toll-like 4 receptor

Buccini

Roriz

Rodrigues

et al. 2022

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

Antimicrobial peptides are part of the organism’s defense system. They are multifunctional molecules capable of modulating the host’s immune system and recognizing molecules present in pathogens such as lipopolysaccharides (LPSs). LPSs are recognized by molecular patterns associated with pathogens known as Toll-like receptors (TLRs) that protect the organism from pathological microorganisms. TLR4 is responsible for LPS recognition, thus inducing an innate immune response. TLR4 hyperstimulation induces the uncontrolled inflammatory process that is observed in many illnesses, including neurodegenerative, autoimmune and psoriasis). Molecules that act on TLR4 can antagonize the exacerbated inflammatory process. In this context, antimicrobial peptides (AMPs) are promising molecules capable of mediating toll-like receptor signaling. Therefore, here we address the AMPs studied so far with the aim of inhibiting the intense inflammatory process. In addition, we aim to explore some of the interactions between exogenous AMPs and TLR4.

show abstract

Editorial: Antimicrobial Peptides: Molecular Design, Structure-Function Relationship, and Biosynthesis Optimization

Cited by 22 publications

References 42 publications

Effect of NZ2114 against Streptococcus dysgalactiae biofilms and its application in murine mastitis model

Effect of NZ2114 against Streptococcus dysgalactiae biofilms and its application in murine mastitis model

Pharmacokinetics and Pharmacodynamics of Fungal Defensin NZX Against Staphylococcus aureus-Induced Mouse Peritonitis Model

Antimicrobial peptides could antagonize uncontrolled inflammation via Toll-like 4 receptor

Contact Info

Product

Resources

About